BiVictriX Therapeutics plc announced that it has appointed Dr Michael Kauffman, M.D., Ph.D. to its Board of Directors as an Independent Non-Executive Director with effect from 17 January 2022. He currently serves on the Boards of Karyopharm Therapeutics Inc, Verastem Oncology, Kezar Life Sciences and Adicet Bio.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | 0.00% | +4.35% | +14.29% |
Jun. 06 | BiVictriX Wins Development Grant for Ovarian Cancer Drug Conjugate | MT |
Jun. 06 | BiVictriX Therapeutics plc Receives Grants to Accelerate Solid Tumour Targeting ADC Pipeline from Innovate UK | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.29% | 12.66M | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- BiVictriX Therapeutics plc Announces Appointment of Michael Kauffman as Independent Non-Executive Director